stockrowImmunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Free cash flow
Immunovant, Inc.'s free cash flow for fiscal 2026 was −$407.3M, compared with −$376.6M in fiscal 2025. Over the twelve months to 30 June 2026 it was −$414.3M. Over the past ten years it has ranged from −$407.3M (fiscal 2026) to −$28.6M (fiscal 2019) — the current reading is the lowest in ten years. Free cash flow has fallen for 7 consecutive fiscal years. Immunovant, Inc. ranks 583rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | −$407.3M | — |
| FY2025 | −$376.6M | — |
| FY2024 | −$214.6M | — |
| FY2023 | −$188.4M | — |
| FY2022 | −$106.4M | — |
| FY2021 | −$83.5M | — |
| FY2020 | −$53.4M | — |
| FY2019 | −$28.6M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$124.4M | — |
| Mar 2026 | −$95.1M | — |
| Dec 2025 | −$92.3M | — |
| Sep 2025 | −$102.5M | — |
| 27 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| MANE Veradermics Incorporated compare | −$123.0M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| PTCT PTC Therapeutics, Inc. compare | −$259.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IMVT Immunovant, Inc. | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)